(Exact name of small business issuer as specified in its charter)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
See Item 7.01 below.
On September 7, 2011, Elorian Landers, a director of Bond Laboratories, Inc. (the "Company"), tendered his resignation as a member of the Board of Directors of the Company, effective September 7, 2011. There was no disagreement with the the Company known to Mr. Landers on any matter relating to the Company's operations, policies or practices.
On September 7, 2011, the Company's investor relation's firm publicly disclosed the Company's preliminary sales results for August 2011. The investor relation's firm reported that the Company generated approximately $1.15 million in sales, compared to approximately $600,000 in August 2010. The August results reported by the Company's investor relation's firm are preliminary only. The Company intends to publicly release results from operations for the quarter ended September 30, 2011 in the ordinary course in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
Bond Laboratories, Inc. |
By: | /s/ Michael Abrams |
Name: Michael Abrams | |
Title: Interim Chief Financial Officer |